Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 08, 2022 4:39pm
161 Views
Post# 35160300

RE:KTRA flying to the moon on one FTD

RE:KTRA flying to the moon on one FTD

Kintara Announced One-for-Fifty Reverse Stock Split in November - go figure.


https://www.prnewswire.com/news-releases/kintara-announces-one-for-fifty-reverse-stock-split-301675130.html


Kintara is one of the Hedge Funds favorite Pump & Dump stocks - according to Yahoo.com


https://finance.yahoo.com/news/10-pump-dump-stocks-hedge-144707244.html

As yahoo reported:
"To illustrate the risk pump and dumps may carry, consider that on August 30, the US Department of Justice issued an arrest warrant for Frederick Sharp, the key accused in a pump and dump scheme and accused of $1 billion worth of illegal sales of stock in penny stock firms. Investors should be cautious of these schemes. For those who want to take advantage of the rise in interest around meme stocks, some shrewd investing techniques can also help turn a tidy profit. For example, following smart money is almost always a good choice. 

However, these hedge funds, which managed close to $5.1 trillion in assets in 2022, are also pouring into pump and dump stocks to make some easy money. The advent of tech-enabled stock trading has transformed the stock market and made these schemes more mainstream. 

On August 3, Kintara Therapeutics unveiled that it has signed a direct equity purchase agreement for up to $20 million investment with a Chicago-based institutional investor - Lincoln Park Capital Fund."

Lincoln Park Capital (LPC) is no stranger to Oncolytics Biotech given that during Brad Thompson's time LPC entered into a similar agreement with ONCY in 2014 that Kintara Therapeutic had announced in August 2022 with LPC.

https://www.newswire.ca/news-releases/oncolytics-biotech-inc-announces-initial-us10-million-investment-and-up-to-us250-million-common-share-purchase-agreement-with-lincoln-park-capital-fund-llc-513826231.html

<< Previous
Bullboard Posts
Next >>